Senior Scientist Cell Therapy
Resume:
Professional Experience
Carisma Therapeutics
Cell Therapy, Senior Scientist– Philadelphia, PA (2022-2023) Responsible for the design and execution of preclinical studies and play a role in the translation of novel mRNA- based gene therapies. An integral part of a small team. Pre-clinically develop and evaluate novel LNP/mRNA based CAR-M candidates against novel targets. Evaluate the pharmacology and mechanism of action of candidate gene therapies in vitro using cell based assays. Identify lead in vivo CAR-M candidates and evaluate the function, charac- teristics, and specificity of novel binders against oncology targets. Execute a variety of in vitro technical skills includ- ing cell isolation, cell culture, transfection, and cell based functional assays. Appropriately analyze data, interpret results, and maintain accurate laboratory notebook records. Prepare and deliver data presentations to manage- ment. Trouble shoot/optimize experiments and procedures. Astrazeneca
Immunology, Scientist– Gaithersburg, MD. (2021-2022) Focus on developing therapeutics for the treatment of Immunological Diseases predominantly in human in-vitro systems. Working with primary and disease tissue-derived cells. Focus research on characterizing novel immunologi- cal pathways in health and disease to aid target validation and drug projects. Johnson & Johnson (Janssen pharmaceuticals)
Exploratory Biology, Scientist– Spring House, PA. (2019-2021) Development of assay methods for evaluation of cell phenotypes and characterization of investigational (large mol- ecule) cell binding and functional activity, primary cell isolation, advanced flow cytometry, high-content imaging and analysis, advanced imaging expertise, developing advanced cell culture techniques (spheroid/organoid 3D complex assays), T cell activation, phenotyping, kinetic binding and cytotoxicity assays, experience developing and executing high content cell-based assays to define target engagement, automation, experience in an oncology, and immunolo- gy focused labs, and familiarity with tumor models and anti-tumor response modelling in 3D spheroid culture Lonza Pharma & Biotech
Cell Therapy, QC Senior Scientist- Portsmouth NH. (2018-2019) Development and optimization of cell culture processes for the production of cell therapy products. Design and exe- cute new unique cell-based projects, execute developed process plans, Tech transfers, Understand and develop cell- based assays .
GlaxoSmithKline
Complex in-vitro Models, Senior Scientist– Collegeville PA. (2016-2018) 2D/3D complex in-vitro models & cell culture, Car-T (CIVM) cellular assays, Cellular & Molecular biology, Automa- tion technologies, Bioprinting, Spheroids/Organoids, and Organs-on-chip for evaluating their feasibility and capabil- ity in drug discovery and development, Set-up, Run, & Maintain 3D cell culture/Tumor-viability/Infiltration models, automate systems for evaluating novel complex in-vitro models & Tissue engineering for Organ-specific functions and/or Disease-modeling, Test and validate Human relevant and translatable complex in-vitro models in support of Immunology, Oncology, Neuroscience, Drug Delivery, Pharmacology/Toxicology, PK/PD modeling, and Systems Biology. Operetta CLS/Phenix High Content Imaging systems, Columbus/Harmony HC Imaging and Analysis soft- ware. High-Content Flow.
Immunology-Inflammation Therapeutic Area (iiTAU), Senior Scientist- Cambridge, MA. (2016-2018) My primary role is to investigate the immunological, molecular, and pharmacological mediators of innate and adap- tive immune cells in relation to immune and inflammatory diseases. Merck and Co.
Immunology Scientist- Boston MA. (2009-2016)
My primary role is to investigate the immunological, molecular, and pharmacological mediators of innate and adap- tive immune cells in relation to immune and inflammatory diseases. Human tissue dissection (testing primary tis- sues and cells), in-vitro studies with Human T-cells, characterization of regulatory T-cell phenotype & functionality, Immunology cell based assays, Treg suppression, activation assays, multi-color flow cytometry, cell culture, im- munohistochemistry, protein and molecular analysis. Prepare animals utilizing sensitization dosing, animal surgery, tissue preparation and processing, execute pharmacological studies, elucidate the molecular mechanisms of lung tissue explants (precision cut lung slice-PCLS) on rat and Human. Develop and utilize target engagement and func- tional assays in tissue and cells around Immunology targets, Molecular biology techniques (ELISA, MSD, PCR, clon- ing, Westerns), Diva, FlowJo, Prism, Softmax Pro, Adobe Creative Suite including Photoshop, Nikon Elements, Leica LAS, Zeiss Zen and LSM 510 software.
Erich E. Sirkowski
Resume/Infographics
507 Bunker Hill Rd. Harleysville Pa. 19438
*****.*********@*****.***
B.Sc. Microbiology/Molecular Genentics
Academics
M.L.A Neuroscience GPA 3.4
Professional Development
Erich E. Sirkowski
Resume/Infographics
314 Andale Green Dr. Lansdale, PA 19446
*****.*********@*****.***
Publications
Erich Sirkowski, (2013) Inhibition of Spleen Tyrosine Kinase Attenuates Allergen Mediated Airway Constriction. Am. J. of Respiratory Cell and Molecular Biology Vol. 49(6):1085-1092. E.E. Sirkowski, (2006) Genetic and physi ological evidence that oligodendrocyte gap junctions contribute to spatial buffering of potassium released during neuronal activity. J. Neurosci. 26(43):109**-*****. E.E. Sirkowski, (2006) ErbB2 signaling in Schwann cells is largely dispensable for maintenance of myelinated periph- eral nerves and proliferation of adult Schwann cells following injury. J. Neurosci. 26(7):2124-2131. E.E. Sirkowski, (2005) Both Laminin and Schwann cell Dystroglycan are necessary for proper clus tering of Sodium Channels at Nodes of Ranvier. J. Neurosci. 25(41):9418-9427. E.E. Sirkowski, (2005) Prenylation-defective human connexin32 mutants are normally localized and function equiva- lently to wild type connexin 32 in myelinating Schwann cells. J. Neurosci. 25(31);7111-7120. E.E. Sirkowski, (2004) Acute demyelination disrupts the molecular organization of PNS nodes. J. Comparative Neurol- ogy, 479:424-434.
E.E. Sirkowski, 2004) Expression analysis of the N-myc downstream-regulated gene 1 (NDRG1) indicates that mye- linating Schwann cells are the primary disease target in hereditary motor and sensory neuropathy Lom. Neurobio- logical Disease, 17(2):290-9.
E.E. Sirkowski, (2003) Connexins are critical for normal myelination in the CNS. J. Neurosci. 22:102**-*****. E.E. Sirkowski, (2002) Identification of genes that are downregulated in the absence of the POU domain transcription factor pou3f1 (Oct-6,Tst-1, SCIP) in sciatic nerve. J. Neurosci. 23:596-5973. Scientific Posters
Society for Neuroscience Poster Presentation-2004
Sirkowski, E.E., S. S. Scherer, P. Berger, and U. Suter Expression analysis of the N-Myc downstream-regulated gene 1 indicates that myelinating Schwann cells are the primary disease target in hereditary motor and sensory neuropathy-Lom. Merck Poster Presentations and Collaborations
• Utility of the Rat Precision Cut Lung Slice (PCLS) to Evaluate Onset of Action and Duration of Action of Syk Inbi- tiors.
• Development of Cell-Based Screen to Identify Autophagy Inducers for the Treatment of Neurodegenerative and Chronic In flammatory Diseases. • Characterization of Responses to Polarizing Stimuli by Immortalized Human Microglia.
• LRKK2 Kinase Inhibitors of Different Structural Classes Induce Abnormal Accumulation of Lamellar Bodies in Type II Pneu mocytes in Non-Human Primates, and are Reversible Without Pulmonary Functional Conse- quences.
Additional Professional Experience
Leica-Microsystems Inc.
Life Sciences Research Microscopy Specialist-Baltimore, Md. (2007-2008) University of Pennsylvania
Department of Neurology, Research Specialist C- Philadelphia PA. (2002-2007) Studies on the cellular and molecular biology of myelinated axons, both in health and disease. Manage transgenic mice (Genetics, Breed- ing, Genotyping, and Animal Husbandry), Prepare animal tissues for light and electron microscopy, including surgery, preparing sections of frozen tissue, teasing nerve fibers, preparing epoxy sections for light and electron microscopy, localize molecules in myelinated fibers by immunolabeling, including epifluorescent microscopy,, Perform transmission electron microscopy of meylinated axons, Cell culture includ- ing transfection, immunostaining and immunoblotting. Department of Pathology, Part Time Research Specialist (2005-2006) Studies on understanding the environmental cues that govern the differen tiation and survival of functionally dis- tinct subpopulations of mature peripheral B-cells. Merck & Co. Inc.
Virus and Cell Biology Research Scientist (Contractor)-West Point, Pa. (2001) Sanofi-Sytnhelabo (Contractor)
Clinical Metabolism Research Scientist–Malvern, Pa. (2001) Cephalon Inc. (Internship)
Department of Neural Molecular Biology-West Chester, Pa. (1996-1997) M.L.A Neuroscience GPA 3.4 (Masters Capstone Thesis- 2007) Descriptive Analysis and Characterization of Voltage-Gated Potassium Channel Kv3.1b.
B.Sc. Microbiology/Molecular Genentics
Academics
M.L.A Neuroscience GPA 3.4
Professional Development
Contact this candidate